Communiqués ALLOVIRPAR

Actions

ALVR

US0198182026

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 05/08/2026			Varia. 5j.	Varia. 1 janv.
4,190 ^USD	-3,01%		+23,24%	-57,29%

19/03/25	Kalaris Therapeutics finalise la fusion avec AlloVir	MT
18/03/25	Kalaris Therapeutics, Inc. a réalisé l'acquisition d'AlloVir, Inc. (NasdaqCM:ALVR) dans le cadre d'une opération de fusion inversée.	CI

Communiqués

28/01	ALLOVIRPAR : Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting	PU
20/03/25	ALLOVIRPAR : March 2025 Corporate Presentation	PU
12/03/25	Kalaris and AlloVir Announce Stockholder Approval of Merger	AQ
10/02/25	ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR	BU
10/11/24	ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR	BU
08/11/24	AlloVir : and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina Form 8 K	PU
08/11/24	AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina	AQ
02/07/24	AlloVir : Termination of Material Agreement Form 8 K	PU
15/03/24	ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	PR
14/03/24	Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm	PR
12/03/24	AlloVir, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR	PR
07/03/24	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR	PR
06/03/24	Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky	PR
27/02/24	Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class Action - ALVR	PR
23/02/24	Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline	PR
22/02/24	Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact The Gross Law Firm	PR
20/02/24	Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for Investors - Contact Levi & Korsinsky	PR
16/02/24	Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR	PR
13/02/24	Class Action Filed Against AlloVir, Inc. (ALVR) - March 19, 2024 Deadline to Join - Contact Levi & Korsinsky	PR
09/02/24	Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More	PR
22/12/23	AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy	AQ
16/11/23	AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference	BU
02/11/23	AlloVir Reports Third Quarter 2023 Financial Results	BU
28/08/23	AlloVir to Present at Upcoming Investor Conferences	BU
03/08/23	AlloVir Reports Second Quarter 2023 Financial Results	BU